Getting in front and behind the enemy lines to counter virus infection.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed.

1. Vaccinal antibodies: Fc antibody engineering to improve the antiviral antibody response and induce vaccine-like effects.Human vaccines & immunotherapeutics · 2021
   Review
2. Fc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseases.Expert review of anti-infective therapy · 2015
   Review

Corrections and comments

• Comment on
  Anatomically restricted synergistic antiviral activities of innate and adaptive immune cells in the skin.2013

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract